Connect with us

Hi, what are you looking for?


Magic Mushrooms and Ecstasy: New Treatment for Autism Spectrum Disorders?

Much like cannabis, psychedelics are catching the eye of investors for their potential to break out of their classification of scheduled substances and move closer to becoming valuable tools in the treatment of mental health issues.

Researchers and public companies are currently gathering substantial evidence in phase 2 and phase 3 clinical trials for the therapeutic potential of psychedelic molecules in indications like PTSD, depression and substance addiction.

For now, autism spectrum disorders have, for the most part, remained outside the realm of psychedelic medicine. However, as research into psychedelics advances, some companies in the space are aiming to create psychedelics-based solutions targeting ailments in this category.

Psilocybin For Autism and Fragile X Syndrome

Autism spectrum disorders can have severe consequences in the lives of patients and their families. With a prevalence of approximately 1 in 54 children in the U.S., the estimated cost of autism for the average family reaches $60,000 a year through the patient’s childhood.

Disorders in this spectrum are some of the most common indications lacking a known cure or overall satisfactory solution. According to the nonprofit Autism Speaks, the economic cost of caring for Americans with autism reached $268 billion in 2015 and would rise to $461 billion by 2025 in the absence of more effective interventions and support across the patient’s life span.

Canadian biotech Nova Mentis Life Science Corp. (CSE: NOVA) (OTCQB: NMLSF) recently announced a partnership with Mycrodose Therapeutics to develop patented psilocybin products to treat neuroinflammatory disorders, with autism in mind.

Psilocybin is also known as the active compound in so-called “magic 


The partnership intends to explore the use of psilocybin-based therapeutics in disorders such as fragile X syndrome and autism spectrum disorder, by using Mycrodose’s patented drug delivery systems with Nova Mentis’s proprietary version of psilocybin.

Dr. Marvin S. Hausman, chairman of Nova’s Scientific Advisory Board, …

Full story available on


Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Post Content Original Post:


Tumbling COVID-19 case counts have some schools around the U.S. considering relaxing their mask rules, but deaths nationally have been ticking up over the...


The dazzling drone display celebrated not only the 25-year anniversary of EDC, but also the brand’s momentous return after a turbulent 2020. EDC Las...


This week, international law enforcement operations went on the offensive, making arrests in numerous countries for ransomware-related activities. […] Original Post: